Download PDF
Thromb Haemost 1985; 54(02): 528-532
DOI: 10.1055/s-0038-1657890
Original Article
Schattauer GmbH Stuttgart

Equal Antiplatelet Effects of Aspirin 50 or 324 mg/Day in Patients After Acute Myocardial Infarction

R De Caterina
The C.N.R. Institute of Clinical Physiology, Pisa, Italy
,
D Giannessi
The C.N.R. Institute of Clinical Physiology, Pisa, Italy
,
A Boem
*   The Division of Cardiovascular Medicine, Spedali Riuniti di S. Chiara, Pisa, Italy
,
W Bernini
The C.N.R. Institute of Clinical Physiology, Pisa, Italy
,
D Battaglia
The C.N.R. Institute of Clinical Physiology, Pisa, Italy
,
C Michelassi
The C.N.R. Institute of Clinical Physiology, Pisa, Italy
,
F Dell’Amico
The C.N.R. Institute of Clinical Physiology, Pisa, Italy
,
A L’Abbate
The C.N.R. Institute of Clinical Physiology, Pisa, Italy
,
P Patrignani
**   The Institute of Pharmacology, Universitá Cattolica del Sacro Cuore, Roma, Italy
,
C Patrono
**   The Institute of Pharmacology, Universitá Cattolica del Sacro Cuore, Roma, Italy
› Author Affiliations
Further Information

Publication History

Received 14 March 1985

Accepted 18 June 1985

Publication Date:
18 July 2018 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

This study explores the effects on some hematological parameters of a low-dose aspirin regimen (50 mg/day) versus a conventional aspirin treatment with reported antithrombotic efficacy (324 mg/day), in patients with acute myocardial infarction. Fifteen patients were randomized into 3 equal groups receiving 50 mg or 324 mg aspirin or placebo, daily for 21 days. Compared with placebo, bleeding time was significantly and similarly prolonged with both aspirin doses (+ 71 ± 22% and + 69 ± 20%, mean ± S.D.). Aspirin 50 mg/day suppressed arachidonate-induced platelet aggregation and secondary phase aggregation after ADP and adrenaline. Collagen aggregation was inhibited by 44 ± 15%. In no case were differences in the antiplatelet effects of the two doses observed. The effects of 50 mg/day persisted without attenuation during the observation period. Platelet thromboxane B2 generation during arachidonate-induced aggregation was inhibited by 95 ± 2 and 99 ± 1% compared to placebo group after 50 and 324 mg/day, respectively (P between doses <0.05). No change was observed with any treatment in coagulation time, prothrombin time or plasma thromboplastin time. Thus, in patients with acute myocardial infarction, the antiplatelet effects of aspirin 50 mg/day are stable over time and superimposable on those of 324 mg/day. The antithrombotic efficacy of aspirin 50 mg/day remains to be tested clinically.

Keywords

Aspirin - Myocardial infarction - Thromboxane - Prostacyclin
 

  • References

  • 1 Roth CJ, Majerus PW. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particular fraction protein. J Clin Invest 1975; 56: 624-632
    CrossrefPubMedSearch in Google Scholar
  • 2 Flower RJ, Moncada S, Vane JR. Analgesic-antipyretics and antiinflammatory agents. In: The Pharmacological Basis of Therapeutics. Goodman-Gilman A, Goodman S, Gilman A. (eds.) MacMillan Publishing Co.; New York: 1980. 682 728
    Search in Google Scholar
  • 3 FitzGerald GA, Pedersen AK, Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 1983; 67: 1174-1177
    CrossrefPubMedSearch in Google Scholar
  • 4 Patrono C, Ciabattoni G, Pinca E, Pugliese F, Castrucci G, De Salvo A, Satta MA, Peskar BA. Low-dose aspirin and inhibition of thromboxane B2 production in healthy subjects. Thromb Res 1980; 17: 317-327
    CrossrefPubMedSearch in Google Scholar
  • 5 FitzGerald GA, Oates JA, Hawiger J, Maas RL, Roberts II LJ, Lawson JA, Brash AR. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. J Clin Invest 1983; 71: 676-688
    CrossrefPubMedSearch in Google Scholar
  • 6 Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. J Clin Invest 1982; 69: 1366-1372
    CrossrefPubMedSearch in Google Scholar
  • 7 De Caterina R, Giannessi D, Bernini W, Gazzetti P, Michelassi C, L’Abbate A, Donato L, Patrignani P, Filabozzi P, Patrono C. Low-dose aspirin in patients recovering from myocardial infarction: Evidence for a selective inhibition of thromboxane-related platelet function. Eur Heart J. (in press)
    PubMed
  • 8 Majerus PW. Arachidonate metabolism in vascular disorder. J Clin Invest 1983; 72: 1521-1525
    CrossrefPubMedSearch in Google Scholar
  • 9 Marcus AJ. Aspirin as an antithrombotic medication. N Engl J Med 1983; 309: 1515-1516
    CrossrefPubMedSearch in Google Scholar
  • 10 Patrono C, Ciabattoni G, Patrignani P, Pugliese F, Filabozzi P, Catella F, Davì G, Forni L. Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation. 1985 (in press)
    PubMedSearch in Google Scholar
  • 11 Lewis DL, Davis JW, Archibald DC, Steinke WE, Smitherman TC, Doherty III JE, Schnaper HW, LeWinter MN, Linares E, Pouget JM, Sabharwal SC, Chesler E, DeMots H. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a Veterans Administration Cooperative Study. N Engl J Med 1983; 309: 396-403
    CrossrefPubMedSearch in Google Scholar
  • 12 Horan LG, Flowers NC. Electrocardiography and vectorcardiography. In: Heart Disease. Braunwald E. (ed.). W. B. Saunders Co.; Philadelphia, London, Toronto: 1980: 235
    Search in Google Scholar
  • 13 Mielke Jr Ch. Template bleeding time: techniques. In: Platelet function testing. Day HJ, Holmsetr H, Zucker MD. (ed). Proceedings DHEW Publication; Bethesda: 1978: 78-87
    Search in Google Scholar
  • 14 Giannessi D, De Caterina R, Gazzetti P, Bernini W, Masini S, Zucchelli GC. Methodological assessment and applications of a radioimmunoassay for thromboxane (TX) B2 to measurement of TXB2 release by platelets. J Nucl Med Allied Sci 1982; 26: 25-33
    PubMedSearch in Google Scholar
  • 15 Zar JH. Biostatistical analysis. Englewood Cliffs. Prentice-Hall, Inc.. (2nd edition)
    PubMed
  • 16 Harter HR, Burch JW, Majerus PW, Stanford N, Delmez JA, Anderson CB, Weerts CA. Prevention of thrombosis in patients on hemodialysis by low-dose aspirin. N Engl J Med 1979; 301: 577-579
    CrossrefPubMedSearch in Google Scholar
  • 17 Lorenz RL, Schacky CV, Weber M, Meister W, Kotzur J, Reichardt B, Theisen K, Weber PC. Improved aortocoronary bypass patency by low-dose aspirin (100 mg daily). Lancet 1984; 01: 1261-1264
    PubMedSearch in Google Scholar
  • 18 Buchanan MR, Rischke JA, Hirsh J. Aspirin inhibitis platelet function independent of the acetylation of cyclooxygenase. Thromb Res 1982; 25: 363-373
    CrossrefPubMedSearch in Google Scholar
  • 19 Weksler BB, Kent JL, Rudolph D, Scherer PB, Levy DE. Effects of low dose aspirin on platelet function in patients with recent cerebral ischemia. Stroke 1985; 16: 05-09
    CrossrefPubMedSearch in Google Scholar
  • 20 McKenna R, Galante J, Bachmann F, Wallace DL, Kaushal SP, Meredith P. Prevention of venous thromboembolism after total knee replacement by high-dose aspirin or intermittent calf and thigh compression. Br Med J 1980; 280: 514-517
    CrossrefPubMedSearch in Google Scholar
  • 21 Hirsch J. Progress review: the relationship between dose of aspirin, side-effects and antithrombotic effectiveness. Stroke 1985; 16: 01-04
    CrossrefPubMedSearch in Google Scholar
  • 22 Nuñez L, Gil Aguado M, Larrea JL, Celemìn D, Oliver J. Prevention of thromboembolism using aspirin after mitral valve replacement with porcine bioprosthesis. Ann Thor Surg 1984; 37: 84-87
    CrossrefPubMedSearch in Google Scholar
  • 23 Cairns J, Gent M, Singer J, Finnie K, Frogatt G, Holder D, Jablonsky G, Kostuk W, Melendez L, Myers M, Sackett D, Sealey B, Tanser P. (abstr.) A study of aspirin (ASA) and/or sulfinpyrazone (S) in unstable angina (UA). Circulation 1984; 70 (Suppl. 02) 415 (Abstr)
    PubMedSearch in Google Scholar
  • 24 FitzGerald GA, Smith B, Pedersen AK, Brash AR. Increased prostacyclin biosynthesis in patients with severe atherosclerosis and platelet activation. N Engl J Med 1984; 310: 1065-1068
    CrossrefPubMedSearch in Google Scholar
  • 25 Sinziger H, O’Grady J, Fitscha P, Kaliman J. Extremely-low-dose aspirin (one milligram per day) renders human platelets more sensitive to anti-aggregatory prostaglandins. N Engl J Med 1984; 311: 1052
    PubMedSearch in Google Scholar
  • 26 The Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. N Engl J Med 1978; 299: 53-59
    CrossrefPubMedSearch in Google Scholar
  • 27 Rajah SM, Penny A, Kester R. Aspirin and bleeding time. Lancet 1978; 01: 1104
    PubMedSearch in Google Scholar
  • 28 O’Grady J, Moncada S. Aspirin: a paradoxical effect on bleeding time. Lancet 1978; 01: 780
    PubMedSearch in Google Scholar
  • 29 Pedersen AK, FitzGerald GA. Dose-related kinetics of aspirin: presystemic acetylation of platelet cyclooxygenase. N Engl J Med 1984; 311: 1211-1214
    CrossrefPubMedSearch in Google Scholar